Waldencast Plc Form 6-K Summary: Sale of Obagi Business
Business Context and Reporting Period
This Form 6-K, dated June 1, 2026, reports the execution of a definitive agreement by Waldencast Plc (the "Company") to sell its Obagi Medical business. The transaction involves the sale of 100% of the equity interests of Obagi Netherlands B.V. and Obagi AsiaPac Limited, and the merger of Obagi Cosmeceuticals LLC into a purchaser entity. The Obagi business is engaged in developing, manufacturing, and selling medical-grade skin care products.
Key Financial Metrics and Transaction Consideration
The filing details the financial structure of the sale rather than the Company's ongoing operating results for the period. Key financial terms include:
- Total Consideration: Up to $460,000,000.
- Cash Component: Approximately $366,000,000, subject to customary adjustments for closing cash, indebtedness, net working capital, and transaction expenses.
- Vendor Notes: $30,000,000 in aggregate, consisting of a $10,000,000 Fixed Vendor Note and a $20,000,000 Adjustable Vendor Note, both maturing 7.5 years post-closing.
- Contingent Consideration: Up to $64,000,000 in earnout payments based on non-injectables revenue milestones for fiscal year 2026 and injectables revenue milestones for fiscal year 2027.
- Debt Repayment: Proceeds will be used to repay all outstanding indebtedness under the Existing Credit Agreement (dated November 14, 2025). This indebtedness will reduce the total consideration on a dollar-for-dollar basis.
The filing does not provide specific revenue, profit, cash flow, or margin figures for the Company or the Obagi business for the reporting period.
Material Changes and Executive Departures
The primary material change is the divestiture of the Obagi business. Concurrent with the transaction:
- Executive Resignations: Michel Brousset (CEO) and Hind Sebti (Chief Growth Officer) will resign from the Company at closing. They will receive cash bonuses, severance, accelerated vesting, and cash settlements, subject to an offset against a $6,000,000 reinvestment obligation.
- Reinvestment Obligation: The Key Executives have committed to co-invest $6,000,000 in the buyer's affiliate (Holdco). This obligation will be satisfied by reducing their severance payments and the consideration payable to the Seller.
- Leadership Transition: Felipe Dutra, current Chairman of the Board, is expected to be appointed as interim CEO at closing.
- Retained Business: The Company will retain the Milk Makeup business, which is not part of the sale.
Guidance, Outlook, Risks, and Conditions
Conditions to Closing: The transaction is subject to customary conditions, including the expiration of the HSR Act waiting period, receipt of approvals from U.S. state Boards of Pharmacy, absence of prohibitory laws, and the absence of a material adverse effect.
Termination Fees: If the Seller terminates the agreement due to a Purchaser breach or failure to close, the Purchaser must pay a reverse termination fee of $16,000,000. The outside date for closing is September 29, 2026, subject to automatic extensions.
Risks and Uncertainties: The filing highlights risks including the inability to satisfy closing conditions, failure to achieve earnout milestones, potential reduction of total consideration, and the impact of the transaction on supplier and customer relationships. The Company notes that the intended use of proceeds has not been finally determined.
Investor Verification Checklist
- Verify the final purchase price adjustments regarding closing cash, indebtedness, and net working capital.
- Confirm the status of regulatory approvals, specifically from U.S. state Boards of Pharmacy.
- Monitor the achievement of the 2026 and 2027 revenue milestones required to trigger the $64,000,000 earnout.
- Review the terms of the $30,000,000 in Vendor Notes and the specific conditions under which the Adjustable Vendor Note may be reduced.
- Assess the Company's strategic plan and capital allocation strategy for the retained Milk Makeup business following the divestiture.